Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Osteosarcoma | 7 | 2023 | 897 | 1.910 |
Why?
|
Bone Neoplasms | 12 | 2023 | 2532 | 1.670 |
Why?
|
Wilms Tumor | 4 | 2024 | 375 | 1.200 |
Why?
|
Rhabdomyosarcoma | 3 | 2024 | 359 | 1.060 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2023 | 42 | 0.850 |
Why?
|
Leiomyosarcoma | 2 | 2022 | 424 | 0.760 |
Why?
|
Gene Fusion | 1 | 2022 | 354 | 0.650 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2019 | 119 | 0.640 |
Why?
|
Sarcoma | 4 | 2022 | 1786 | 0.580 |
Why?
|
Specimen Handling | 2 | 2020 | 707 | 0.550 |
Why?
|
Germ Cells | 3 | 2024 | 635 | 0.530 |
Why?
|
Kidney Neoplasms | 5 | 2024 | 4312 | 0.510 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2023 | 3616 | 0.510 |
Why?
|
Drug Synergism | 1 | 2019 | 1754 | 0.480 |
Why?
|
Small Molecule Libraries | 2 | 2019 | 734 | 0.460 |
Why?
|
Epigenomics | 2 | 2019 | 936 | 0.460 |
Why?
|
Antigens, Nuclear | 1 | 2014 | 184 | 0.450 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 186 | 0.410 |
Why?
|
Nucleotides | 2 | 2023 | 450 | 0.340 |
Why?
|
Genomics | 6 | 2022 | 5794 | 0.310 |
Why?
|
Child | 25 | 2024 | 79806 | 0.300 |
Why?
|
RNA-Binding Protein EWS | 5 | 2021 | 210 | 0.290 |
Why?
|
Oncogene Proteins, Fusion | 5 | 2022 | 1596 | 0.280 |
Why?
|
Neoplasms | 7 | 2022 | 22072 | 0.270 |
Why?
|
Cell Cycle Proteins | 4 | 2024 | 3446 | 0.260 |
Why?
|
DNA | 3 | 2023 | 7233 | 0.250 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5643 | 0.250 |
Why?
|
Vincristine | 2 | 2024 | 1039 | 0.240 |
Why?
|
Proto-Oncogene Protein c-fli-1 | 3 | 2021 | 104 | 0.240 |
Why?
|
Hydrazines | 2 | 2024 | 224 | 0.230 |
Why?
|
Phthalimides | 1 | 2024 | 34 | 0.230 |
Why?
|
Piperidones | 1 | 2024 | 37 | 0.230 |
Why?
|
Gene Expression Regulation, Neoplastic | 6 | 2021 | 8515 | 0.230 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2013 | 2418 | 0.220 |
Why?
|
Mice, Nude | 4 | 2019 | 3607 | 0.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 11712 | 0.210 |
Why?
|
Cyclin-Dependent Kinase 4 | 2 | 2016 | 556 | 0.200 |
Why?
|
Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2021 | 44 | 0.190 |
Why?
|
High-Throughput Screening Assays | 2 | 2019 | 944 | 0.190 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 301 | 0.190 |
Why?
|
Cyclophosphamide | 2 | 2024 | 2221 | 0.190 |
Why?
|
Morpholines | 1 | 2024 | 583 | 0.180 |
Why?
|
Karyopherins | 2 | 2024 | 130 | 0.180 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2022 | 218 | 0.180 |
Why?
|
Triazoles | 2 | 2024 | 904 | 0.180 |
Why?
|
Cell Line, Tumor | 10 | 2024 | 16939 | 0.170 |
Why?
|
Humans | 44 | 2024 | 760621 | 0.170 |
Why?
|
Prognosis | 5 | 2023 | 29658 | 0.160 |
Why?
|
Carcinoma, Medullary | 1 | 2019 | 115 | 0.160 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2021 | 3584 | 0.150 |
Why?
|
Resource Allocation | 1 | 2020 | 349 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2024 | 9276 | 0.150 |
Why?
|
Colonic Polyps | 1 | 2022 | 551 | 0.140 |
Why?
|
Sirolimus | 1 | 2024 | 1547 | 0.140 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 2 | 2024 | 854 | 0.140 |
Why?
|
Mutation | 7 | 2024 | 29932 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2024 | 1056 | 0.130 |
Why?
|
Chromosome Aberrations | 1 | 2022 | 1764 | 0.130 |
Why?
|
Sequence Analysis, DNA | 2 | 2018 | 4713 | 0.130 |
Why?
|
Histone Demethylases | 1 | 2018 | 323 | 0.130 |
Why?
|
Aminopyridines | 1 | 2019 | 564 | 0.120 |
Why?
|
Apoptosis | 4 | 2024 | 9501 | 0.120 |
Why?
|
Cyclin D1 | 1 | 2015 | 451 | 0.110 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1313 | 0.100 |
Why?
|
Quinazolines | 1 | 2019 | 1363 | 0.100 |
Why?
|
Adolescent | 12 | 2024 | 87810 | 0.100 |
Why?
|
RNA | 1 | 2022 | 2722 | 0.100 |
Why?
|
Ribonucleoproteins | 1 | 2014 | 372 | 0.100 |
Why?
|
RNA, Neoplasm | 1 | 2014 | 749 | 0.100 |
Why?
|
Mice | 7 | 2022 | 81208 | 0.100 |
Why?
|
Prospective Studies | 5 | 2024 | 54303 | 0.100 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 6131 | 0.090 |
Why?
|
Zebrafish | 2 | 2021 | 2997 | 0.090 |
Why?
|
Rare Diseases | 1 | 2016 | 619 | 0.090 |
Why?
|
Indoles | 1 | 2019 | 1829 | 0.090 |
Why?
|
Doxorubicin | 3 | 2024 | 2209 | 0.090 |
Why?
|
Sequence Analysis, RNA | 4 | 2022 | 2005 | 0.090 |
Why?
|
Lentivirus | 1 | 2013 | 506 | 0.090 |
Why?
|
Genetic Heterogeneity | 1 | 2013 | 724 | 0.080 |
Why?
|
Biopsy | 2 | 2020 | 6771 | 0.080 |
Why?
|
Gene Rearrangement | 1 | 2014 | 1122 | 0.080 |
Why?
|
Down-Regulation | 2 | 2014 | 2913 | 0.080 |
Why?
|
Sulfonamides | 1 | 2019 | 1977 | 0.080 |
Why?
|
DNA, Neoplasm | 1 | 2014 | 1745 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2919 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2019 | 6498 | 0.080 |
Why?
|
RNA Interference | 4 | 2019 | 2846 | 0.080 |
Why?
|
Nuclear Proteins | 2 | 2021 | 5791 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2024 | 3602 | 0.080 |
Why?
|
Animals | 9 | 2022 | 167963 | 0.080 |
Why?
|
Drug Discovery | 1 | 2015 | 1057 | 0.070 |
Why?
|
Enzyme Inhibitors | 1 | 2018 | 3726 | 0.070 |
Why?
|
Oncogenes | 1 | 2013 | 1220 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2022 | 11152 | 0.070 |
Why?
|
Child, Preschool | 5 | 2024 | 42063 | 0.070 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2009 | 226 | 0.070 |
Why?
|
Female | 15 | 2024 | 391270 | 0.070 |
Why?
|
Cell Survival | 2 | 2015 | 5797 | 0.070 |
Why?
|
Proteomics | 1 | 2019 | 3817 | 0.060 |
Why?
|
Survival Analysis | 1 | 2018 | 10182 | 0.060 |
Why?
|
Flow Cytometry | 2 | 2013 | 5870 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2014 | 2828 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3426 | 0.060 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2021 | 2506 | 0.060 |
Why?
|
Mice, Inbred NOD | 2 | 2021 | 1837 | 0.060 |
Why?
|
Dactinomycin | 1 | 2024 | 304 | 0.060 |
Why?
|
Retrospective Studies | 3 | 2022 | 80372 | 0.060 |
Why?
|
Point Mutation | 1 | 2009 | 1594 | 0.060 |
Why?
|
Transcription Factors | 2 | 2024 | 12103 | 0.060 |
Why?
|
Cohort Studies | 3 | 2024 | 41335 | 0.060 |
Why?
|
Neoplasm Transplantation | 2 | 2019 | 2014 | 0.060 |
Why?
|
Young Adult | 7 | 2024 | 58741 | 0.060 |
Why?
|
Membrane Transport Proteins | 1 | 2009 | 1035 | 0.060 |
Why?
|
HEK293 Cells | 1 | 2013 | 4264 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2019 | 10446 | 0.050 |
Why?
|
Folic Acid | 1 | 2009 | 1309 | 0.050 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2024 | 435 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2022 | 6853 | 0.050 |
Why?
|
Genomic Imprinting | 1 | 2023 | 330 | 0.050 |
Why?
|
Phosphorylation | 1 | 2013 | 8313 | 0.050 |
Why?
|
POU Domain Factors | 1 | 2021 | 47 | 0.050 |
Why?
|
Etoposide | 1 | 2023 | 630 | 0.050 |
Why?
|
Adult | 9 | 2024 | 219994 | 0.050 |
Why?
|
Germ-Line Mutation | 2 | 2022 | 1841 | 0.050 |
Why?
|
Infant | 5 | 2024 | 36060 | 0.050 |
Why?
|
Biology | 1 | 2023 | 290 | 0.040 |
Why?
|
Male | 9 | 2024 | 359744 | 0.040 |
Why?
|
Recurrence | 2 | 2016 | 8482 | 0.040 |
Why?
|
Tissue Banks | 1 | 2020 | 184 | 0.040 |
Why?
|
Cell Cycle | 2 | 2019 | 2934 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2013 | 11071 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 886 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2021 | 329 | 0.040 |
Why?
|
Epigenesis, Genetic | 2 | 2023 | 3758 | 0.040 |
Why?
|
Gene Amplification | 1 | 2023 | 1085 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 15789 | 0.040 |
Why?
|
Molecular Targeted Therapy | 2 | 2022 | 2803 | 0.040 |
Why?
|
Protein Stability | 1 | 2019 | 566 | 0.040 |
Why?
|
Colectomy | 1 | 2022 | 692 | 0.030 |
Why?
|
Translocation, Genetic | 1 | 2021 | 1388 | 0.030 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2021 | 727 | 0.030 |
Why?
|
Syndrome | 1 | 2022 | 3280 | 0.030 |
Why?
|
Antibodies, Monoclonal | 2 | 2023 | 9185 | 0.030 |
Why?
|
Gene Expression | 2 | 2022 | 7588 | 0.030 |
Why?
|
Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2014 | 15 | 0.030 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2019 | 633 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2023 | 2013 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2019 | 1697 | 0.030 |
Why?
|
Enhancer Elements, Genetic | 1 | 2021 | 1356 | 0.030 |
Why?
|
Alternative Splicing | 1 | 2019 | 1091 | 0.030 |
Why?
|
Colonoscopy | 1 | 2022 | 1387 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 838 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 717 | 0.030 |
Why?
|
DNA Replication Timing | 1 | 2013 | 34 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2013 | 65017 | 0.030 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2013 | 95 | 0.030 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2015 | 346 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2015 | 13630 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2023 | 6828 | 0.030 |
Why?
|
DNA Damage | 1 | 2022 | 2442 | 0.030 |
Why?
|
Survival Rate | 1 | 2006 | 12808 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 558 | 0.030 |
Why?
|
Homeodomain Proteins | 1 | 2021 | 2414 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2015 | 1173 | 0.020 |
Why?
|
Genetic Testing | 1 | 2024 | 3531 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2013 | 956 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2016 | 1347 | 0.020 |
Why?
|
Mice, SCID | 1 | 2015 | 2627 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2016 | 1440 | 0.020 |
Why?
|
Proton-Coupled Folate Transporter | 1 | 2009 | 3 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2022 | 17790 | 0.020 |
Why?
|
Sample Size | 1 | 2013 | 840 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2021 | 5785 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8555 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1895 | 0.020 |
Why?
|
DNA Methylation | 1 | 2023 | 4373 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3844 | 0.020 |
Why?
|
Genotype | 1 | 2023 | 12960 | 0.020 |
Why?
|
Cell Movement | 1 | 2021 | 5206 | 0.020 |
Why?
|
Intestinal Absorption | 1 | 2009 | 400 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6898 | 0.020 |
Why?
|
Transfection | 1 | 2015 | 5781 | 0.020 |
Why?
|
Leucovorin | 1 | 2009 | 641 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2525 | 0.020 |
Why?
|
Up-Regulation | 1 | 2014 | 4122 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 4902 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2006 | 39261 | 0.020 |
Why?
|
Artifacts | 1 | 2013 | 1898 | 0.010 |
Why?
|
Immunophenotyping | 1 | 2009 | 1871 | 0.010 |
Why?
|
Pyridines | 1 | 2016 | 2879 | 0.010 |
Why?
|
Signal Transduction | 2 | 2018 | 23376 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7064 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2022 | 18137 | 0.010 |
Why?
|
Middle Aged | 3 | 2023 | 220352 | 0.010 |
Why?
|
Parents | 1 | 2016 | 3549 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9585 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26181 | 0.010 |
Why?
|
Genome, Human | 1 | 2013 | 4417 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2009 | 6068 | 0.010 |
Why?
|
Risk Factors | 1 | 2006 | 74359 | 0.010 |
Why?
|
Base Sequence | 1 | 2009 | 12446 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 25942 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 20080 | 0.010 |
Why?
|
Genetic Variation | 1 | 2009 | 6551 | 0.010 |
Why?
|
Time Factors | 1 | 2015 | 40165 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2009 | 10181 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13262 | 0.000 |
Why?
|
Aged | 1 | 2016 | 169152 | 0.000 |
Why?
|
Concepts
(208)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(87)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_